The U.S. Department of Justice (DOJ) is investigating potential illegal activity at UnitedHealth Group, related to the insurer’s billing practices, according to a report published Friday by the Wall Street Journal.
Per the outlet, UnitedHealth is being probed for upcoding Medicare Advantage claims. Specifically, the DOJ is looking into whether the insurer is responsible for billing the Centers for Medicare & Medicaid Services (CMS) for patient diagnoses not applicable to the actual care a patient will need, in an effort to boost monthly payments received through the program.
For its coverage, the Wall Street Journal cites sources familiar with the case. According to reporters, the DOJ has spoken with providers about the alleged upcoding, which could have led to the insurer pocketing billions of extra reimbursement dollars.
The Wall Street Journal also reported that the Department of Health and Human Services Office of Inspector General (OIG) is supporting the DOJ investigation. However, neither agency has released a statement.
UnitedHealth quickly responded, issuing its own statement Friday morning, calling the claims made by the Wall Street Journal “misinformation” and adding that the outlet has a history of misleading the public about the Medicare Advantage program.
“We are not aware of the ‘launch’ of any ‘new’ activity as reported by the Journal,” the company said. “We are aware, however, that the Journal has engaged in a year-long campaign to defend a legacy system that rewards volume over keeping patients healthy and addressing their underlying conditions.”
Last summer, reporters digging into billions of medical claim records found that insurers may be responsible for $50 billion in fraud related to Medicare Advantage, receiving payments for “hundreds of thousands of questionable diagnoses that triggered extra taxpayer-funded payments,” including for deadly illnesses that “people couldn’t possibly have.”
Those incidents are said to have occurred between 2019 and 2021.
For more, read the full exclusive from the Wall Street Journal at the link below.
Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.
The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.
The ACC, AHA, HFSA, HRS and SCAI all worked together to try and make the new board a reality. Though their proposal has been denied, the groups say they are not done fighting.
The Outsourcing Facilities Association, a Texas-based trade group, is alleging that supply issues still remain for Ozempic and Wegovy. The group believes the FDA has ignored those issues.